Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Datoo MS. et al, (2021), Lancet

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary KRW. et al, (2021), The Lancet, 397, 1351 - 1362

Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination.

Müller K. et al, (2021), EMBO molecular medicine, 13

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262

Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum

Milne K. et al, (2021), eLife, 10

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

COVID-19 Vaccines: Global Challenges and Prospects Forum Recommendations.

Boudjelal M. et al, (2021), Int J Infect Dis

Malaria is a cause of iron deficiency in African children.

Muriuki JM. et al, (2021), Nat Med

COVID-19 vaccines for rapid global impact.

Hill AVS., (2021), BJU Int, 127, 137 - 139

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Immunological considerations for SARS-CoV-2 human challenge studies

Douglas AD. and Hill AVS., (2020), Nature Reviews Immunology, 20, 715 - 716

Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule

Rollier CS. et al, (2020), Scientific Reports, 10

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Native American gene flow into Polynesia predating Easter Island settlement

Ioannidis AG. et al, (2020), Nature, 583, 572 - 577

Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells.

Bowyer G. et al, (2020), The Journal of experimental medicine, 217

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826

Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency.

Gilchrist JJ. et al, (2020), BMC medicine, 18

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?